How much revenue does Cisen Pharmaceutical make?

Cisen Pharmaceutical reported 3.98 billion CNY in revenue for fiscal year 2024, down 10.8% from 4.46 billion CNY in fiscal year 2023. In Q2 2025 revenue was 819.57 million CNY.

Where does Cisen Pharmaceutical make most of its revenue?

China: 98% of revenue by region in fiscal year 2025, followed by Overseas (2%).

What companies are similar to Cisen Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Beijing Foyou Pharma Co.,ltd (601089.SS), Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ), Dezhan Healthcare Company Limited (000813.SZ), Hunan Warrant Pharmaceutical Co.,Ltd (688799.SS).

Cisen Pharmaceutical Co., Ltd. (603367.SS) Stock

About Cisen Pharmaceutical Co., Ltd.

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and an...

At a glance

Cisen Pharmaceutical reported revenue of 3.98 billion CNY for fiscal year 2024, down 10.8% from fiscal year 2023, and net income of 508.91 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 819.57 million CNY, down 11.1% from a year before. China was its largest region in fiscal year 2025, with 98% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.